Atreca's net income is $-95M, below the Healthcare sector average of $17B.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2023
Trailing 12 months ending Sep 2023
Loading...
Loading...
The latest net income for BCEL is $-95M as of September 2023. That compares with $-110M in the prior-year period — up 10.1% year over year. That is below the Healthcare sector average of $17B. Investors often review this figure alongside Atreca's historical trend and sector peers before judging valuation or financial health.
Over the past year, BCEL's net income moved from $-110M to $-95M — a 10.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Atreca's operating scale or balance-sheet position.
Against Healthcare companies, BCEL currently prints $-95M for net income, while the sector average sits near $17B. That is roughly 100.6% below the sector mean. Large gaps often invite a closer look at Atreca's growth, margins, and balance sheet.
A net income figure of $-95M for BCEL is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $17B. Explore the charts below for those layers of context.
After noting BCEL's net income ($-95M), review year-over-year change from $-110M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.